Abstract
Aim: To assess the efficacy of Semaglutide on liver steatosis/fibrosis indexes. Methods: Observational, multicenter study. Steatosis/fibrosis were determined by HSI (<30 rule out, >36 steatosis) and FIB-4 (<1.3 rule out, >2.67 fibrosis) . Results: 213 patients (46.9% women) , age 64 (19) years. Variables and 24 wk changes are shown in table 1. 100% of patients had altered steatosis biomarkers (HSI 47.9 (8.2)) , 10.8% fibrosis (FIB-4> 2.76) . A significant reduction in HSI [-2.36 (95%CI 1.83-2.9) p<0.0000] and FIB-4 [-0.075 (95%CI0.015-0.14) p<0.016] were found (Table 1) . There was a correlation between weight loss and HSI, GGT or TyG improvement (figure 1) . Conclusion: Our results show a beneficial effect of Semaglutide on steatosis that goes beyond glucose control, and it is related mainly with weight loss and decline in biomarkers. Disclosure J.Carretero gomez: None. F.Carrasco-sánchez: None. J.Fernandez: Advisory Panel; Boehringer Ingelheim International GmbH, Daiichi Sankyo, Lilly Diabetes, Novartis Pharmaceuticals Corporation, Sanofi Genzyme, Speaker's Bureau; Amgen Inc., Novo Nordisk Foundation. P.Casado: None. P.Diabetes, nutrition and obesity working group of s: n/a. J.Arevalo lorido: None. J.Miramontes gonzález: None. J.Segí-ripoll: None. J.Ena: None.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
